Rheum to Grow: Considerations For Making a Smooth Transition From Pediatric-to-Adult Rheumatology Care

Theater A | Supported By: Pfizer

---

Program Description

In this session, experts will discuss the current state of transition of care from pediatric to an adult rheumatologist, including challenges and helpful resources to optimize the process. The role of JAK inhibitors, approved for both appropriate pediatric and adult patients, will also be explored.

This program is developed and offered by Pfizer. This is not an official program of the American College of Rheumatology.